- Published at
- by manilatimes.net
neutral
neutral
News for Ipsen S.A. (IPNN.MX)
- Published at
- by seekingalpha.com
neutralneutralIpsen S.A. Non-GAAP EPS of €10.27, revenue of €3.4B; initiates FY25 outlook
Ipsen S.A. press release (IPSEY): FY Non-GAAP EPS of €10.27. Revenue of €3.4B (+8.6% Y/Y). FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin- Published at
- by manilatimes.net
mixedmixed- Published at
- by financialpost.com
mixedmixedIpsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase i…- Published at
- by seekingalpha.com
neutralneutralIpsen S.A. reports Q3 results; raises FY24 guidance
Ipsen S.A. (IPSEY) reported Q3 revenue of €836.6M. Based on the strong performance in the third quarter, Ipsen has further increased its financial guidance for 2024.- Published at
- by investing.com
positivepositiveEton Pharmaceuticals acquires rare disease drug Increlex By Investing.com
Eton Pharmaceuticals acquires rare disease drug Increlex- Published at
- by globenewswire.com
mixedmixedPeptide Therapeutics Market to Witness 5.94% CAGR by 2031 | SkyQuest Technology
Peptide Therapeutics Market size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period...ZLDPFZEALAMGN.MXAMGN.BAAMGNAMG.DETKPHFTAKP34.SATAKN.MXTAKPTGX4502.T4502.S0A87.LZEG.DEPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFENVSN.MXNVSEFNVSD.BANVSNVON.MXNVONOVOBN.MXNOVN.SWNOVC.DENOVA.DENONOFN1VS34.SAMRKD.BAMRK.SNMRK.PAMRK.MXMRKLLY.MXLLY.DELLY.BALLYLILY34.SAIPSEYIPNN.MXIPN.PABRM.DEBMYB34.SABMY.MXBMY.BABMYBFEHFBANB.SWAZNN.MXAZNCFAZN.LAZN6MK.DE0TDD.L0QND.L0Q1G.L0K9E.L0A4J.L- Published at
- by seekingalpha.com
neutralneutralIpsen S.A. Non-GAAP EPS of €4.78, revenue of €1.66B; raises FY24 outlook
Ipsen S.A. press release (IPSEY): 1H Non-GAAP EPS of €4.78. Revenue of €1.66B (+7.8% Y/Y). Full-year 2024 guidance We have upgraded our financial guidance for 2024:- Published at
- by marketscreener.com
positivepositiveMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of...- Published at
- by marketscreener.com
neutralneutralIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the...- Published at
- by seekingalpha.com
positivepositiveIpsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors (IPSEY)
Ipsen S.A. partners with Sutro Biopharma, Inc. to develop a pre-clinical antibody drug candidate. Read more on IPSEF and STRO stock here.- Published at
- by marketscreener.com
mixedmixedMerrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. today announced its full year 2023 financial results for the period ended December 31, 2023. “As Ipsen reported in February, the U.S. Food and Drug...- Published at
- by globenewswire.com
mixedmixedHuman Growth Hormone Market Size to be Worth USD 3.9 billion by 2031, with Notable CAGR of 3.7 %| Transparency Market Research, Inc.
A long-acting formulation or novel delivery route could influence the human growth hormone market significantly....- Published at
- by financialpost.com
mixedmixedDeutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com- Published at
- by globenewswire.com
mixedmixedDeutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com...- Published at
- by globenewswire.com
mixedmixedInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on...- Published at
- by asiaone.com
mixedmixedInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 GlobeNewswire November 01, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday,...- Published at
- by globenewswire.com
positivepositiveHuman Growth Hormone Market is forecasted to Reach USD 11.8 Billion by 2032, growing at an 8.4% CAGR from 2023 to 2032
Acumen Research and Consulting recently published report titled “Human Growth Hormone Market Forecast, 2023 - 2032”...- Published at
- by financialpost.com
mixedmixedInternational companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) — Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on…- Published at
- by globenewswire.com
mixedmixedInternationale Unternehmen veranstalten Live-Webcasts auf der Depositary Receipts Virtual Investor Conference der Deutschen Bank am 16. und 17. Mai 2023
NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Die Deutsche Bank hat heute das Programm für ihre Depositary Receipts Virtual Investor Conference („dbVIC“) am...